AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.
AdvanCell has raised $315.0M in total funding. The most recent round was Series D. The last funding was announced in July 2026.
AdvanCell's investors include Eli Lilly, Alpha Wave Global, Catalio Capital Management, Bain Capital Life Sciences, SV Health Investors.
AdvanCell is headquartered in Sydney, Australia.
AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.
AdvanCell is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AdvanCell — Funding & Investors." VCBacked, July 15, 2026, https://www.vcbacked.co/company/advancell. Accessed August 14, 2026.
VCBacked. (2026). AdvanCell — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/advancell
{{cite web |title=AdvanCell — Funding & Investors |url=https://www.vcbacked.co/company/advancell |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated